'First-In-Human' directed pre-clinical development of anti-cancer agent CYC140

Cyclacel开发了一种临床候选NCE，其特点是能够靶向以前未开发的治疗食管癌（OEC）的机制，这是一种高度未满足需求的孤儿疾病。这种强效和选择性PLK1激酶抑制剂具有很强的临床前基础，可作为OEC和其他具有特定驱动突变的实体肿瘤适应症的分层药物使用。该药物开发项目包括临床前验证用于患者临床分层的标记分析，“首次人体”（FIH）指导的安全性研究，临床配方和第一阶段测试的生产，以及在目标疾病模型中与已批准和正在研究的治疗药物联合测试化合物。成功将为英国和欧盟的开发项目吸引更多的投资，确保额外的就业机会，并将为患有预后不良疾病的实体瘤患者提供一种新的研究药物。

Cyclacel has developed a clinical candidate NCE with characteristics enabling the targeting of a previously unexploited mechanism for treatment of oesophageal cancer (OEC), an orphan disease with a high unmet need. This potent and selective PLK1 kinase inhibitor has a strong preclinical rationale for use as a stratified medicine for OEC and other solid tumour indications having particular driver mutations. The drug development project encompasses preclinical validation of marker assays for clinical stratification of patients, 'First-In-Human' (FIH)-directed safety studies, clinical formulation and manufacture for Phase 1 testing, and testing of the compound in combination with approved and investigational therapeutic agents in models of the target diseases. Success will attract further investment in a UK and EU based development program, securing additional jobs and will provide access to a new investigational medicine for solid tumour patients with poor prognosis diseases.